|
Aug 5
|
Iterum Therapeutics Reports Second Quarter 2025 Financial Results
|
|
Jul 29
|
Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025
|
|
Jul 2
|
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jun 30
|
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth
|
|
Jun 25
|
Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence
|
|
Apr 14
|
Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics
|
|
Oct 10
|
Iterum Therapeutics to Present Data at IDWeek 2024
|
|
Oct 9
|
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit
|
|
Aug 16
|
When Will Iterum Therapeutics plc (NASDAQ:ITRM) Become Profitable?
|
|
Aug 14
|
Iterum Therapeutics Reports Second Quarter 2024 Financial Results
|
|
Aug 2
|
Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem
|
|
Jun 21
|
Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
|
|
Mar 29
|
Q4 2023 Iterum Therapeutics PLC Earnings Call
|
|
Mar 28
|
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Dec 4
|
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule
|
|
Nov 15
|
Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2023 Earnings Call Transcript
|
|
Nov 15
|
Q3 2023 Iterum Therapeutics PLC Earnings Call
|
|
Nov 14
|
Iterum Therapeutics Reports Third Quarter 2023 Financial Results
|
|
Aug 4
|
Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023
|